Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 7/20 | 0.49 |
| ▸ | XIAP | P98170 | 16/20 | 0.42 |
| ▸ | BIRC3 | Q13489 | 4/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075889 | 1.00 | BIRC2 (0.49) | BIRC2XIAPBIRC3CPT2CPT1A | |
| SCHEMBL10076784 | 0.95 | BIRC2 (0.46) | BIRC2XIAPBIRC3CPT2CPT1A | |
| SCHEMBL10076365 | 0.94 | BIRC2 (0.43) | BIRC2XIAPBIRC3CPT2CPT1A | |
| SCHEMBL10076386 | 0.92 | BIRC2 (0.46) | BIRC2XIAPBIRC3 | |
| SCHEMBL10075882 | 0.89 | XIAP (0.44) | BIRC2XIAPBIRC3LMNA | |
| SCHEMBL10075887 | 0.88 | BIRC2 (0.47) | BIRC2XIAPBIRC3CPT1ALMNA | |
| SCHEMBL13475971 | 0.88 | BIRC2 (0.39) | BIRC2XIAPBIRC3CPT2CPT1A | |
| SCHEMBL10075867 | 0.88 | BIRC2 (0.44) | BIRC2XIAPBIRC3 | |
| SCHEMBL10075881 | 0.87 | XIAP (0.47) | BIRC2XIAPBIRC3 | |
| SCHEMBL10076586 | 0.87 | BIRC2 (0.46) | BIRC2XIAPBIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009141-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | PHARMASCIENCE INC. (CA) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009141-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | BIRC5, BIRC7, BIRC2 | BIRC2 3/4885XIAP 4/4885BIRC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.